<prompt> TNF-alpha inhibitor isInfliximabEfalizumabMannose-6-phosphateDecorin  <response>: A Infliximab Harrison18-2491; GG12-1018; Il,h-I419; ANTI-TNF-ALPHA INHIBITORS: Adalimumab, etanercept, and infliximab are antibodies that bind TNF alfa a proinflammatory cytokine. Blocking TNF alfa from binding to TNF receptors on inflammatory cell surfaces results in suppression of downstream inflammatory cytokines such as IL-1 and IL-6 and adhesion molecules involved in leukocyte activation and migration. An increased risk of lymphoma is common to each of these agents. Infliximab is a human-mouse chimeric lgG1 monoclonal antibody possessing human constant Fc regions and murine var able regions. Infliximab is currently approved for use in Crohns disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Efalizumab is a recombinant humanized anti-CD11 a monoclonal antibody approved for the treatment of adult patients with severe psoriasis. Binding of Efalizumab to CD11a the alpha subunit of LFA-1 inhibits the interaction of LFA-1 on all lymphocytes with intercellular adhesion molecule-1 ICAM-1, thereby inhibiting the adhesion, activation, and migration of lymphocytes into skin. Efalizumab is administered by subcutaneous injection.Infliximab is a monoclonal antibody against TNF. It is used to treat autoimmune diseases. Decorin Mannose-6-phosphates are TGF-beta inhibitors. 